FedEx trackedLot COA librarySupport 8:00 AM – 9:00 PM ETFree shipping on orders $85+

Research community

πŸ”₯ Hot Today in Peptide Research

Last updated

Man carrying a surfboard along the beach at sunset

FDA peptide compounding notice: White House review log now lists six outside meetings, text still unpublished. Updated daily.

FDA Peptide Compounding Policy Tracker 2026: status and timeline of the interim notice, the July advisory votes and the 503A bulks list.

πŸ”₯πŸ”₯

FDA peptide compounding notice: White House review log now lists six outside meetings, text still unpublished

Woman road cycling on a mountain road at sunrise

Photo: BioLabs Research

The White House Office of Information and Regulatory Affairs (OIRA) still listed the FDA notice 'Interim Access Policy for Compounding Using Certain Peptides' (RIN 0910-ZD94) as pending review on 24 October 2026, ten days after receiving it. OIRA's public log now shows six meetings with outside parties between 21 and 28 October, requested by a peptide-medicine academy, a telehealth company, a compounding trade group, a consumer-advocacy group and two consultancies for their clients. The records show who asked to meet, not what was said; the notice text, covered substances and any conditions remain unpublished, and a pending review is not a published policy or an FDA approval.

Read the Full Update

For research-community awareness only. Not legal advice.

Curated for research-community awareness. Not medical or legal advice. All products on this site are for laboratory research use only.